Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension

CARY, N.C. and BASEL, Switzerland — Oct. 22, 2019 — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of pulmonary arterial hypertension (PAH). These data were presented as a poster […] Read More »

Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019

CARY, N.C. and BASEL, Switzerland — Oct. 18, 2019 — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians’ annual CHEST 2019 meeting being held October 19 – […] Read More »

Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl

Cary, N.C. and BASEL, Switzerland – Oct. 1, 2019 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced new clinical data from two Phase 1 trials of rodatristat ethyl, demonstrating favorable safety and tolerability in healthy volunteers, and mechanistic biomarker data [...] Read More »

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Cary, N.C. and BASEL, Switzerland – Sep. 24, 2019 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will present clinical safety, pharmacokinetic and biomarker data from two Phase 1 clinical studies of rodatristat ethyl at the 29th International Congress of the European […] Read More »

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients

Sumitomo Dainippon-Roivant Alliance (“Alliance”) encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation Sumitomo Dainippon Pharma to enter into contract agreements with Roivant Health technology Vants including […] Read More »

Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA’s Annual PHPN Symposium

Cary, N.C. and BASEL, Switzerland – Sep 5, 2019 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced a poster presentation describing the company’s unique, patient-centric drug development process at the Pulmonary Hypertension Association’s Annual PH Professional Network (PHPN) Symposium taking place September 5-7, 2019 in Washington, D.C. Patient […] Read More »

August 5, 2019

Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension

Cary, N.C. and BASEL, Switzerland – Aug 5, 2019 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that it has dosed the first patient in the ELEVATE 1 proof-of-concept Phase 2a study of the company’s lead candidate, rodatristat ethyl, in patients with pulmonary arterial hypertension (PAH). […] Read More »

May 9, 2019

Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit

Cary, N.C. and BASEL, Switzerland – May 9, 2019 – Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, today announced that it has been invited to present at the 2019 Respiratory Innovation Summit (RIS) being held May 17 in Dallas, […] Read More »

January 31, 2019

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

Basel, Switzerland and Durham, N.C. – Jan. 31, 2019 – Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular […] Read More »

January 2, 2019

Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer

BASEL, Switzerland and DURHAM, N.C. — Jan. 2, 2019 — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension and other indications, today announced the appointment of Lyn Baranowski as Chief Operating Officer. In this new position, she will be involved in the general management of […] Read More »

Media

Roivant Pipeline Day

Altavant CEO Bill Symonds presents

Get in Contact

info@altavant.com

Media inquiries: Monique Allaire

monique@thrustsc.com

Patient Engagement Publications

A Framework for Engaging PAH Patients in the Drug Development Process

5 September 2019 Pulmonary Hypertension Association’s Annual PH Professional Network (PHPN) Symposium; Washington, D.C.

Mascherino L.

View Original Publication »